BioSpace News Archive

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian,

Surgery Partners, Inc., a leading short-stay surgical facility owner and operator, announced a change in the format for the Company’s 2020 annual meeting of stockholders by filing additional proxy materials with the Securities and Exchange Commission.

Today, the U.S. Food and Drug Administration approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”).

DexCom, Inc. announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. has been changed and will be held as a hybrid meeting that stockholders can attend either in person or virtually via live webcast, though the Company strongly encourages stockholders to participate virtually.

21st Century Oncology, the largest integrated cancer care network in the nation, has completed the joint venture partnership with Landmark Cancer Center.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Adamas Pharmaceuticals,. today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 66,000 shares of the company’s common stock, at a per share exercise price of $3.46, the closing trading price on May 7, and restricted stock units to acquire 33,000 shares of the company’s common stock.

MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced that it is repaying the Payment Protection Program Loan received through its application to the Federal relief effort.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC),